A Phase 1, Single-Center, Dose-Escalation Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF614 in Healthy Subjects Compared to OxyContin®
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Oxycodone (Primary)
- Indications Pain
- Focus Adverse reactions
- Acronyms SAD
- Sponsors Ensysce Biosciences
- 03 Apr 2017 Status changed from recruiting to completed, according to an Ensysce Biosciences media release.
- 17 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Apr 2017.
- 02 Jan 2017 According to an Ensysce Biosciences media release, initial data will be presented at the 9th Annual Biotech Showcase 2017.